Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardiaSOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of s ...

SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit's latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of solutions to improve cardiac interventions, including the HeartSpan®, Worley™, Prelude SNAP™, and SafeGuard Focus® pr ...

SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To acc ...

Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.SOUTH JORDAN, Utah, March 27, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the American Society for Gastrointestinal Endoscopy (ASGE) updated its guideline on the diagnosis and management of gastroesophageal reflux disease (GERD) to include Transoral Incisionless Fundoplication (TIF 2.0) and TIF 2.0 Consecutive Transo ...

Merit Medical Systems (MMSI) released 12-month efficacy results for its WRAPSODY Cell-Impermeable Endoprosthesis (“CIE”), demonstrating strong performance in vascular access maintenance. Designed to enhance long-term outcomes for patients with end-stage renal disease, WRAPSODY CIE leverages advanced technology to improve vessel patency and reduce complications.This milestone underscores Merit Medical's dedication to innovation in interventional medicine. With promising clinical data, WRAPSODY CIE reinforces ...

At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target lesion primary patency and access circuit primary patency, respectively. SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Acc ...

SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 A.M. "Merit’s listing on Nasdaq for 35 years marks a significant milestone in our company’s history,” said Lampropo ...

Group 1 - Medical technology companies have experienced a "flight to safety" in 2025, benefiting from increased investor interest [1] - Merit Medical (NASDAQ: MMSI) has outperformed the market, with shares rising nearly 20% since the last analysis [1]

Merit Medical Systems, Inc. (MMSI) , on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in premature infants (PREEMIE study). The PREEMIE study is an Investigational Device Exemption study.It should be noted that the Bloom Micro Occluder System is not currently approved to treat PDA.MMSI plans to enroll at least 55 premature infants with hemodynamically significant or large PDA ...

Core Insights - Merit Medical Systems, Inc. has initiated a multicenter, prospective study named PREEMIE to evaluate the safety and efficacy of the Bloom Micro Occluder System for treating patent ductus arteriosus (PDA) in premature infants [1][4] - The Bloom Micro Occluder System is designed as a minimally invasive treatment option for hemodynamically significant PDAs, utilizing a flexible delivery system to insert a self-expanding nitinol device [3][4] - The study aims to enroll at least 55 premature infants weighing between 600 g and 2,500 g across up to ten U.S. study sites, with a focus on assessing safety and efficacy over a six-month period [3][4] Company Overview - Merit Medical Systems, Inc. was founded in 1987 and specializes in the development, manufacture, and distribution of proprietary medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy [5] - The company has a global presence with a sales force and clinical support team of over 800 individuals and employs approximately 7,400 people worldwide [5] Industry Context - Patent ductus arteriosus (PDA) is a common congenital heart condition in premature, low-birth-weight infants, which can negatively impact health and often requires treatment [2] - Current treatment options for PDA in small premature infants are limited, making the Bloom Micro Occluder System a potentially significant advancement in pediatric interventional cardiology [4]